Ying Huang

Bank of America commented on Biogen Inc (NASDAQ: BIIB) Wednesday following the death of a patient due to fatal progressive multifocal leukoencephalopathy (PML) that was linked to dimethyl fumarate (DMF). Dimethyl fumarate is the active ingredient in Biogen’s multiple sclerosis drug,...

In a report published Monday, Bank of America analyst Ying Huang reiterated a Neutral rating and $179.00 price target on Amgen, Inc. (NASDAQ: AMGN). In the report, Bank of America noted, "The U.S. District Court for the Northern District of California has denied AMGN's request for an injunction...

Bank of America downgraded Gilead Sciences, Inc. (NASDAQ: GILD) Monday from Buy to Underperform and cut its price target from $130 to $87. The downgrade follows news of AbbVie Inc’s (NYSE: ABBV)

In a report published Friday, Bank of America analyst Ying Huang reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $418.00 to $462.00. In the report, Bank of America noted, “We are raising our sales estimates for REGN's two late-stage pipeline...

In a report published Tuesday, Bank of America analyst Ying Huang reiterated a Neutral rating and $119.00 price target on Vertex Pharmaceuticals (NASDAQ: VRTX). In the report, Bank of America noted, “We held a conference call yesterday with the director of a large cystic fibrosis center following...

In a report published Tuesday morning, Barclays analyst Ying Huang initiated coverage on GlycoMimetics (NASDAQ: GLYC). Barclays kick off the GLYC coverage with an Overweight rating and price target of $15. The report highlights the company's progress "Currently GlycoMimetics has one partnered...

In a report published Thursday, Barclays analyst Ying Huang downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Overweight to Underweight, and lowered the price target from $25.00 to $4.00. In the report, Barclays noted, “We are downgrading ARIA to UW from OW and reducing our price...